



# FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP  
600 CONGRESS AVENUE, SUITE 2400  
AUSTIN, TEXAS 78701-3271  
WWW.FULBRIGHT.COM

1648  
RECEIVED


DEC 30 2002

TECH CENTER 1600/2900

MARK B. WILSON  
PARTNER  
MBWILSON@FULBRIGHT.COM

DIRECT DIAL: (512) 536-3035  
TELEPHONE: (512) 474-5201  
FACSIMILE: (512) 536-4598

December 12, 2002

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231, on the date below:	
December 12, 2002	
Date	Mark B. Wilson

Commissioner for Patents  
Washington, D.C. 20231

Re: SN 09/993,363 "INDUCTION OF IMMUNITY USING INHIBITORS OF GRANZYMES" by Philip G. Ashton-Rickardt and Joseph T. Opferman -  
Client Ref. UCHI:917  
Our Ref. ARCD:382US/10109293


Commissioner:

Enclosed for filing in the above-referenced patent application is:

- (1) A Response to Restriction Requirement dated November 12, 2002; and
- (2) A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.

Should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No.: 50-1212/ARCD:382US.

Very truly yours,



Mark B. Wilson  
Reg. No. 37,259

MBW/vv  
Enclosure

25241744.1



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:  
Philip G. Ashton-Rickardt  
Joseph T. Opferman

Serial No.: 09/993,363

Filed: November 14, 2001

For: INDUCTION OF IMMUNITY USING  
INHIBITORS OF GRANZYMES

Group Art Unit: 1648

Examiner: Mary Mosher

Atty. Dkt. No.: ARCD:382US/MBW

PATENT

#2 Election  
11/7/03  
**RECEIVED**

DEC 30 2002

TECH CENTER 1600/2900

CERTIFICATE OF MAILING  
37 C.F.R. § 1.8

I hereby certify that this correspondence is being deposited  
with the U.S. Postal Service as First Class Mail in an  
envelope addressed to: Commissioner for Patents,  
Washington, D.C. 20231, on the date below:

December 12, 2002

Date

Mark B. Wilson

**RESPONSE TO RESTRICTION REQUIREMENT AND SPECIES ELECTION**  
**REQUIREMENT DATED NOVEMBER 12, 2002**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

This paper is submitted in response to the Restriction Requirement and Species Election Requirement dated November 12, 2002, for which the date for response is December 12, 2002.

No fees are believed due with this response. However, should any fee under 37 C.F.R. §§ 1.16 to 1.21 be deemed required for any reason pertaining to this paper, consider this paragraph a request and authorization to withdraw the appropriate fee from Fulbright & Jaworski Deposit Account No. 50-1212/10109293/01999.

**A. Restriction Requirement**

In response to the restriction requirement imposed by the Examiner, Applicants elect without traverse, to prosecute claims 1-25, *i.e.*, the **Group I** claims, which are directed to therapeutic method using a granzyme inhibitor, (class 514, subclass 2).

**B. Species Election Requirement**


The Examiner has also entered a Species Election Requirement and subdivided all the Groups I, II and III inventions as containing claims to "species of disease treated" and identified the following diseases: HIV, LCMV, HCV, HTLV-1, HTLV-2, EBV, HBV, HCMV, HSV-1, HSV-2, HGV, enterovirus, dengue, rabies, melanoma, colon cancer, prostate cancer, renal cancer, non-Hodgkin lymphoma, sarcoma, B-cell leukemia, lung cancer and breast cancer. In this regard, Applicants currently elect HIV, as a species for initial examination. However, if any generic claim, such as 1, 16, 20, 23, 24, or 25 is allowed, Applicants reserve the right to reintroduce claims to the remaining species in the present case.

The Examiner has also entered another Species Election Requirement and required the election of a single species of inhibitor and listed the following species: antibody, small molecule, PI9 mimetic, SPI6, PI9, PI-6, MNEI, PI-8, and PAI-2. In this regard, Applicants currently elect PI9, as a species for initial examination. However, if any generic claim, such as 1, 4, 5, 6, or 12 is allowed, Applicants reserve the right to reintroduce claims to the remaining species in the present case.

C. Conclusion

Applicants respectfully request favorable consideration of this case in view of the above. Should the Examiner have any questions, comments, or suggestions relating to this case, the Examiner is invited to contact the undersigned Applicants' representative at (512)-536-3035.

Respectfully submitted,



Mark B. Wilson

Reg. No. 37,259

Attorney for Applicant

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
512-536-3035  
Date: December 12, 2002